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Abstract
Background: Candidates for preoperative or intraoperative nodal assessment among patients with non-small cell
lung cancer (NSCLC) manifesting as a subsolid tumor are not established. The present study was conducted to
demonstrate the distribution of nodal metastasis rate according to newly proposed T categories for subsolid
tumors, and we further aimed to identify radiologic parameters that can be predictive of nodal metastasis.
Methods: We retrospectively reviewed cases of NSCLC manifesting as a subsolid tumor in computed tomography
scans in a university-affiliated tertiary hospital between April 2013 and August 2016. All patients underwent
mediastinal lymph node dissection during resection surgery. Multivariate analysis was performed among clinical
and radiologic parameters.
Results: Of the 269 eligible patients, T-categories were classified as cTis (n = 23, 8.6%), cT1 (n = 203, 75.5%), and cT2
(n = 43, 16.0%). Ten patients (3.7%) had nodal metastasis: pN1 (n = 5, 1.9%), pN2 (n = 5, 1.9%). Nodal metastasis was
not observed in tumors with a solid part ≤1.0 cm (cT1mi and cT1a) or in nonsolid tumors ≤3.0 cm (cTis). The nodal
metastasis rate in cT1b, cT1c, and cT2 tumors was 6.1% (4/65), 8.3% (1/12), and 11.7% (5/43), respectively. Multivariate
analysis showed that a solid part size > 1.5 cm [odds ratio, 5.89; 95% confidence interval, 1.25–27.68, p = 0.025] was
significantly associated with nodal metastasis.
Conclusions: We observed nodal metastasis from cT1b tumors (solid part size > 1 cm) among proposed T categories
for subsolid tumors and a solid part size is an important radiologic parameter predictive of nodal metastasis in NSCLC
manifesting as a subsolid tumor. Considering the low rate of nodal metastasis, pathologic nodal assessment may be
unnecessary in early T category tumors with a small solid part size.
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Background
The considerable increase in lung cancer screening has
recently led to issues such as an increased number of
lung nodules discovered via computed tomography (CT)
and the management of these lesions. The subsolid nod-
ule, defined as a well-demarcated lung lesion containing
a ground-glass opacity, exhibits different behaviors from
a solid nodule and accordingly, has garnered much
attention. In 2013, the Fleischner Society recommenda-
tions emphasized that from a management perspective,
both pure and part-solid ground-glass nodules are best
considered as a category separate from purely solid lesions
[1]. Subsequently, many studies have investigated subsolid
nodules, and consequently, the recently proposed eighth
tumor-node-metastasis staging system includes more
detailed T1 categories of subsolid nodules, compared to
previous versions [2].
Accurate nodal staging is fundamental in diagnosing
and treating non-small cell lung cancer (NSCLC). Gen-
erally, the nodal metastasis rate in patients with NSCLC
manifesting as a subsolid nodule has been known to be
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low [3–5]. Therefore, it is questionable whether pre-
operative or intraoperative nodal assessment is needed.
Recently updated National Comprehensive Cancer Net-
work guidelines state that preoperative pathologic medi-
astinal evaluation is optional for solid tumors < 1.0 cm
and purely non-solid tumors < 3.0 cm with radiologic
negative mediastinum [6] because of the low rate of me-
diastinal metastasis. Intraoperative nodal assessment in
this situation is also controversial, and there is no con-
sensus. Currently, many clinicians conduct intraopera-
tive nodal assessment based on their experiences.
Given this background, the present study was con-
ducted to demonstrate the distribution of nodal metasta-
sis rate according to newly proposed T categories for
subsolid tumors. For selecting candidates for preopera-
tive or intraoperative nodal assessment, we further
aimed to identify radiologic parameters that can be
predictive of nodal metastasis.
Methods
We selected patients with surgically resected NSCLC
manifesting as a subsolid tumor on CT scans in a uni-
versity affiliated-tertiary hospital from April 2013 to Au-
gust 2016. All patients underwent mediastinal lymph
node dissection (MLND) during resection surgery. The
patient’s clinical data, radiologic features, and pathologic
results were retrospectively reviewed.
The definitions of nodal zone and nodal station were
based on the International Association of the Study of
Lung Cancer (IASLC) lymph node map [7]. The patho-
logic diagnoses were based on the 2011 IASLC classifica-
tion [8]. Real-time endobronchial ultrasound (EBUS)
was performed in selected patients. Rapid on-site evalu-
ation was not conducted during EBUS procedure.
We described radiologic features of a subsolid tumor
based on expert thoracic radiologists’ reports. In the
present study, we defined a subsolid tumor as a mass (>
3 cm) or nodule (≤3 cm) that contained ground-glass le-
sions on CT images. The total tumor (including ground
glass portion around solid part) and solid part size were
measured as the maximum diameters on the lung win-
dow setting. Subsolid tumors less than or equal to 3 cm
were classified according to recently proposed T categor-
ies [2].T categories were classified by the total tumor
and solid part size; cTis (total tumor size of 0.6–3.0 cm
with no solid part), cT1 (total tumor size of 0.6–3.0 cm
with solid part size 0.6–3.0 cm) and cT2 (total tumor
size of 3.0–7.0 cm with any solid part size).
If a total tumor measured 3 cm to 7 cm, it was catego-
rized as cT2 regardless of the solid part size. Cases with
multiple tumors were excluded. A tumor was considered
central if it was visualized within the inner third of the
lung field or abutted mediastinal structures on CT or
positron emission tomography (PET) images. Radiologic
N staging was determined from CT scans with or with-
out PET findings. Lymph nodes with shortest diameters
of > 1 cm on CT and/or a maximum standardized up-
take value > 2.5 on PET were considered metastatic.
Pathologic N stage was determined by the final patho-
logic report after surgery.
All data are presented as mean values (± standard devia-
tions) for continuous variables and numbers (percentages)
for categorical variables. Data were compared between de-
fined groups using the Mann–Whitney test for continuous
variables and Fisher’s exact test for categorical variables. A
linear-by-linear association was defined using Pearson’s
Table 1 Clinical, radiologic and pathologic characteristics of patients
Characteristic Total (n = 269)
Age, years 62.4 ± 10.4
Male sex 115 (42.8)
Former/Current smoker 90 (33.5)
Previous extra-thoracic malignancy 34 (12.6)
Previous lung cancer 6 (2.2)
Tumor centrality 14 (5.2)
Radiologic N stage
N0 227 (84.4)
N1–2 42 (15.6)
T categories for subsolid tumora
cTis 23 (8.6)
cT1 203 (75.5)
cT2 43 (16.0)
EBUS 99 (36.8)
Operation extent
Segmentectomy 41 (15.2)
Lobectomy 228 (84.8)
Pathology
AAH/AIS 2 (0.7)
MIA 29 (10.8)
Invasive ADC 235 (87.4)
Invasive mucinous ADC 3 (1.1)
Pathologic N stageb
N0 259 (96.3)
N1 5 (1.9)
N2 5 (1.9)
Data are presented as n (%) or mean ± standard deviation
AAH atypical adenomatous hyperplasia, ADC adenocarcinoma, AIS
adenocarcinoma in situ, EBUS endobronchial ultrasound, MIA minimally
invasive adenocarcinoma
aT categories were classified by the total tumor size (cm) and solid part size
(cm). Total tumor size was defined as a size including ground glass around the
solid part; cTis (total tumor size of 0.6–3.0 cm with no solid part), cT1 (total
tumor size of 0.6–3.0 cm with solid part size 0.6–3.0 cm) and cT2 (total tumor
size of 3.0–7.0 cm with any solid part size)
bPathologic N stage was determined by the final pathologic report after surgery
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coefficient and performed to test the trends of ordinal
scales in categorical variables.
Significant variables from clinical and radiologic data
identified in the univariate analysis were used for multi-
variate analysis to elucidate predictive factors of nodal me-
tastasis. SPSS 22.0 (IBM, Armonk, NY, USA) was used for
the statistical analyses. A p value < 0.05 was considered
statistically significant.
Results
A total of 269 eligible patients were identified, and their
baseline characteristics are summarized in Table 1. The
patients had a mean age of 62.4 ± 10.4 years. One hun-
dred fifteen patients (42.8%) were male, and 90 (33.5%)
were former or current smokers. Fourteen (5.2%) pa-
tients had a centrally located tumor. The tumors were
categorized into three groups: cTis (n = 25, 8.9%), cT1
(n = 212, 75.7%), and cT2 (n = 43, 15.4%). There were no
cases presenting as a nonsolid tumor less than 0.5 cm.
Ninety-nine (36.8%) patients underwent EBUS prior to
resection surgery, and 228 patients (84.8%) underwent
lobectomy. The most frequent tissue pathology was in-
vasive adenocarcinoma (n = 235, 84.8%). We identified
10 patients with nodal metastasis: pN1 (n = 5, 1.9%) and
pN2 (n = 5, 1.9%).
Patients with more advanced clinical T category fre-
quently underwent EBUS and lobectomy (Table 2). In cT1
tumors, the pN1 and pN2 rates were 1.5 and 1.0%, re-
spectively, whereas there was no nodal metastasis in cTis
tumors. In cT2 tumors, the pN1 and N2 rates were 4.7
and 7.0%, respectively. More advanced T tumors had
significantly more advanced nodal metastasis. In addition,
invasive adenocarcinomas were frequently diagnosed in
advanced T tumors.
The distribution of nodal metastasis in tumors classi-
fied by the proposed clinical T categories is detailed in
Table 3. Nodal metastasis was observed in tumors in
which the solid part was > 1.0 cm or total tumor size >
3.0 cm. There was no nodal metastasis in cTis, cT1mi,
and cT1a tumors. The nodal metastasis rates in cT1b,
cT1c, and cT2 tumors were 6.1% (4/65), 8.3% (1/12),
and 11.7% (5/43), respectively. The mean solid part size
in cT2 tumors (2 cases were nonsolid tumors) was 2.0 ±
1.0 cm.
The detailed information of patients with nodal metasta-
sis is presented in Table 4. All patients had a solid part ex-
ceeding 1 cm. Only one patient had a centrally located
tumor. Most cases of metastatic N1 involved a peribron-
chial node, and 3 of 5 cases of metastatic N2 involved a
subcarinal node. Tumors with nodal metastasis were inva-
sive adenocarcinoma with acinar, papillary, or solid subtype.
Four patients with pN2 underwent EBUS prior to surgery.
One patient (patient number 9) was diagnosed with pN2
disease by EBUS, and subsequently underwent surgery due
to single N2. Other cases (patient number 7, 8, 10) were di-
agnosed with pN2 disease by surgery.
We performed a multivariate analysis to identify the
risk factors predictive of nodal metastasis (Table 5). The
multivariate analysis included variables that were identi-
fied as significant in the univariate analysis. A solid part
Table 2 Differences between cTis, cT1 and cT2 tumors
Variables cTis (n = 23) cT1 (n = 203) cT2 (n = 43) p Value
EBUS 0.000
Not performed 21 (91.3) 134 (66.0) 15 (34.9)
Performed 2 (8.7) 69 (34.0) 28 (65.1)
Operation extent 0.009
Segmentectomy 5 (21.7) 36 (17.7) 0 (0.0)
Lobectomy 18 (78.3) 167 (82.3) 43 (100.0)
Pathologic N stage 0.039
N0 23 (100.0) 198 (97.5) 38 (88.4)
N1 0 (0.0) 3 (1.5) 2 (4.7)
N2 0 (0.0) 2 (1.0) 3 (7.0)
Pathology 0.002
AAH/AIS 0 (0.0) 2 (1.0) 0 (0.0)
MIA 7 (30.4) 22 (10.8) 0 (0.0)
Invasive ADC 16 (69.6) 176 (86.7) 43 (100.0)
Invasive mucinous ADC 0 (0.0) 3 (1.5) 0 (0.0)
Data are presented as n (%)
AAH atypical adenomatous hyperplasia, ADC adenocarcinoma, AIS adenocarcinoma in situ, EBUS endobronchial ultrasound, MIA minimally
invasive adenocarcinoma
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size > 1.5 cm [odds ratio (OR), 5.89; 95% confidence
interval (CI), 1.25–27.68, p = 0.025] was found to associ-
ate significantly with nodal metastasis.
Discussion
In our cohort, the nodal metastasis rate was 3.7% (1.9%
with both pN1 and pN2). Among part-solid nodules
(cT1a-cT1c), the pN1 and pN2 rates were 1.5 and 1.0%,
respectively, whereas there was no nodal metastasis in
cTis (nonsolid nodule ≤3 cm). These findings of low in-
cidence of nodal metastasis are consistent with previous
studies [4, 5, 9].
When tumors were classified by the proposed new T
categories, any nodal metastasis was observed from
cT1b to cT2 tumors, in which the solid part size was >
1.0 cm or total tumor size > 3.0 cm. In the final patho-
logic reports, patients with nodal metastasis had adeno-
carcinoma with invasive subtypes. There was no early
stage adenocarcinoma (e.g., adenocarcinoma in situ
(AIS), minimally invasive adenocarcinoma (MIA), lepidic
predominant adenocarcinoma (LPA)). These findings
suggest that preoperative pathologic nodal evaluation or
extended lymph node assessment might be unnecessary
when early stage adenocarcinomas are suspected by
radiologic features.
It is debatable whether extended lymph node assessment
should be performed in patients with early stage NSCLC. As
noted earlier, the incidence of nodal metastasis in NSCLCs
manifesting as a subsolid tumor is lower than in NSCLCs
with pure solid tumor. Furthermore, the extent of intraoper-
ative node assessment (e.g., selective sampling vs. systematic
dissection) in NSCLC patients remains controversial [10].
Although more extended node dissection has positive effects
on clinical outcomes [11, 12], it is important to consider
various procedure-related morbidities. Flores et al. com-
pared 151 cases of NSCLC (subsolid nodules) with MLND
and 52 cases of NSCLC without MLND [13]. They observed
no differences in survival and asserted that performing
MLND is not mandatory when screen-diagnosed NSCLC
manifests as a subsolid nodule.
Currently available guidelines recommend that preopera-
tive pathologic mediastinal evaluation (e.g., EBUS) should
be considered regarding tumor size, radiologic N status,
and tumor centrality [14, 15]. However, they do not suggest
recommendations exclusively for subsolid tumors. In the
Table 4 Detailed characteristics of patients with nodal involvementa
Patient
number
Total
tumor size
Solid
part size
T stage Central Tumor N Stage (CT) N Stage (PET) EBUS pN stage Involved N1 Involved N2 Pathology/
Subtype
1 3.0 1.7 cT1b No 0 0 Yes pN1 Interlobar – ADC/papillary
2 1.8 1.4 cT1b No 0 0 Yes pN1 Peribronchial – ADC/solid
3 4.1 2.3 cT2 No 0 2 Yes pN1 Peribronchial – ADC/acinar
4 3.2 3.1 cT2 No 0 0 Yes pN1 Peribronchial – ADC/papillary
5 2.7 1.2 cT1b No 0 0 Yes pN1 Peribronchial – ADC/acinar
6 3.7 2.8 cT2 No 0 0 No pN2 Peribronchial 2,3,4 ADC/papillary
7 3.2 1.3 cT2 Yes 0 0 Yes pN2 – 6 ADC/acinar
8 5.4 2.0 cT2 No 0 2 Yes pN2 Peribronchial 7 ADC/acinar
9 2.7 2.6 cT1c No 1 0 Yes pN2 Peribronchial 7 ADC/acinar
10 2.4 1.8 cT1b No 0 0 Yes pN2 – 7 ADC/papillary
ADC adenocarcinoma, CT computed tomography, EBUS endobronchial ultrasound, PET positron emission tomography
aFour patients with pN2 underwent EBUS prior to surgery. One patient (patient number 9) was diagnosed with pN2 disease by EBUS, and subsequently
underwent surgery due to single N2. Other cases (patient number 7, 8, 10) were diagnosed with pN2 disease by surgery
Table 3 Distribution of nodal metastasis in tumors classified by proposed clinical T categoriesa
Categories Total tumor Sizeb (cm) Solid part Size (cm) pN0 pN1 pN2
cTis 0.6–3.0 0 23 (100.0) 0 (0.0) 0 (0.0)
cT1mi ≤3.0 ≤0.5 46 (100.0) 0 (0.0) 0 (0.0)
cT1a 0.6–3.0 0.6–1.0 80 (100.0) 0 (0.0) 0 (0.0)
cT1b 1.1–3.0 1.1–2.0 61 (93.8) 3 (4.6) 1 (1.5)
cT1c 2.1–3.0 2.1–3.0 11 (91.7) 0 (0.0) 1 (8.3)
cT2c 3.0–7.0 Any 38 (88.4) 2 (4.7) 3 (7.0)
aThe nodal metastasis rate was significantly different among classified T categories (P = 0.033)
bDefined as a size including ground glass portion around the solid part
cTwo cases were nonsolid tumors, and the mean solid part size was 2.0 ± 1.0 cm
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present study, multivariate regression analysis showed that
solid part size (> 1.5 cm) is predictive of nodal metastasis.
Previous studies focused on importance of solid consistency
for predicting nodal metastasis in NSCLCs. Koike et al. sug-
gested 89% solid consistency (proportion of solid part size
in total tumor size including ground glass) as a cutoff value
to predict mediastinal metastasis in clinical IA NSCLCs
[16]. Gao et al. reported that an occult N2 risk was lower in
tumors with a ground glass component than in tumors
without, among T1–2 N0 NSCLCs determined by PET CT
[17]. Ye et al. asserted that ground glass status (part solid
or pure solid vs nonsolid) is more accurate predictor than
tumor diameter in clinical IA adenocarcinoma [4]. How-
ever, these studies included numbers of pure solid tumors,
not only subsolid tumors. Our study’s strength is that only
cases of NSCLC manifesting as subsolid tumors were in-
cluded. This is an important finding because solid part size
can be a determinant radiologic criterion when preopera-
tive pathologic nodal assessments are performed.
Tumor size has been considered an important risk fac-
tor for predicting nodal metastasis, and preoperative
pathologic nodal assessment was considered in cases of
tumor exceeding 3 because of low negative predictive
value of PET-CT for detecting mediastinal nodal metasta-
sis [18, 19]. However, total tumor size including ground
glass was not a significant predictive factor (Table 5). The
relatively small number of cT2 cases might have contrib-
uted to this result. Moreover, data from Table 2 shows that
the nodal metastasis rate was significantly higher in cT2
tumors than in cTis or cT1 tumors. We believe that total
tumor size is still worthy as an important predictive radio-
logic factor, as well as solid part size.
In our study, we did not find an association between
tumor centrality and nodal metastasis, although tumor
location has been considered an important factor related
to NSCLC. In a study by Lee et al. [20] of 221 patients
with clinical IA NSCLC with a radiologically negative
mediastinum, the frequency of central tumor location
was 23%, with a higher incidence of pN2 disease relative
to peripherally located tumors. However, only 5.2% of
tumors in the present study were centrally located, and
primary lung adenocarcinomas were generally located
peripherally. Moreover, the term “tumor centrality” is
vague even among radiologists. Hence, the ability of tumor
centrality to predict nodal metastasis should be evaluated
in future studies.
There are some limitations in our study. First, because
of the retrospective design nature, selection bias may
have affected the results. EBUS and lobectomy were per-
formed more frequently in more advanced T categories
(Table 2). Therefore, it is assumed that clinicians did not
actively conduct preoperative or intraoperative nodal as-
sessment in patients with early stage NSCLCs (AIS,
MIA, and LPA). Indeed, we identified 376 surgically
resected NSCLCs manifesting as a subsolid tumor dur-
ing the study period and excluded 107 patients who did
not undergo MLND. Second, the actual nodal metastasis
rate was low because we included only subsolid tumors.
Hence, logistic regression analysis showed widened con-
fidence intervals for the odds ratios, subsequently indi-
cating statistically weak data. Future studies correcting
these limitations are needed.
Conclusions
Among the proposed T categories for subsolid nodules, we
observed nodal metastasis from cT1b, in which the solid
part size exceeded 1 cm. The nodal metastasis rate was
3.7%, and solid part size is an important radiologic param-
eter predictive of nodal metastasis in NSCLC manifesting
as a subsolid tumor. Considering the low rate of nodal me-
tastasis, pathologic nodal assessment may be unnecessary
in early T category tumors with a small solid part size.
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